Instituto de Ciencias del Corazón (ICICOR), CIBER-CV, Hospital Clínico Universitario de Valladolid, C/Ramón y Cajal 3, 47005, Valladolid, Spain.
Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
J Nephrol. 2020 Aug;33(4):737-745. doi: 10.1007/s40620-020-00790-5. Epub 2020 Jun 29.
Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite its international aggressive extension, with a significant morbidity and mortality, the impact of renal function on its prognosis is uncertain.
Analysis from the international HOPE-Registry (NCT04334291). The objective was to evaluate the association between kidney failure severity on admission with the mortality of patients with SARS-CoV-2 infection. Patients were categorized in 3 groups according to the estimated glomerular filtration rate on admission (eGFR > 60 mL/min/1.73 m, eGFR 30-60 mL/min/1.73 m and eGFR < 30 mL/min/1.73 m).
758 patients were included: mean age was 66 ± 18 years, and 58.6% of patient were male. Only 8.5% of patients had a history of chronic kidney disease (CKD); however, 30% of patients had kidney dysfunction upon admission (eGFR < 60 mL/min/1.73 m). These patients received less frequently pharmacological treatment with hydroxychloroquine or antivirals and had a greater number of complications such as sepsis (11.9% vs 26.4% vs 40.8%, p < 0.001) and respiratory failure (35.4% vs 72.2% vs 62.0%, p < 0.001) as well as a higher in-hospital mortality rate (eGFR > 60 vs eGFR 30-60 vs and eGFR < 30, 18.4% vs 56.5% vs 65.5%, p < 0.001). In multivariate analysis: age, hypertension, renal function, 0 saturation < 92% and lactate dehydrogenase elevation on admission independently predicted all-cause mortality.
Renal failure on admission in patients with SARS-CoV-2 infection is frequent and is associated with a greater number of complications and in-hospital mortality. Our data comes from a multicenter registry and therefore does not allow to have a precise mortality risk assessment. More studies are needed to confirm these findings.
新型冠状病毒病(COVID-19)是由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的疾病。尽管它在国际上迅速蔓延,具有较高的发病率和死亡率,但肾功能对其预后的影响尚不确定。
来自国际 HOPE-登记处(NCT04334291)的分析。目的是评估入院时肾功能衰竭严重程度与 SARS-CoV-2 感染患者死亡率之间的关系。根据入院时估计肾小球滤过率(eGFR>60 mL/min/1.73 m、eGFR 30-60 mL/min/1.73 m 和 eGFR<30 mL/min/1.73 m)将患者分为 3 组。
共纳入 758 例患者:平均年龄为 66±18 岁,58.6%为男性。仅有 8.5%的患者有慢性肾脏病(CKD)病史;然而,入院时 30%的患者有肾功能障碍(eGFR<60 mL/min/1.73 m)。这些患者较少接受羟氯喹或抗病毒药物的药物治疗,且并发症更多,如败血症(11.9%比 26.4%比 40.8%,p<0.001)和呼吸衰竭(35.4%比 72.2%比 62.0%,p<0.001),住院死亡率更高(eGFR>60 比 eGFR 30-60 比 eGFR<30,18.4%比 56.5%比 65.5%,p<0.001)。多变量分析显示:年龄、高血压、肾功能、入院时 0 饱和度<92%和乳酸脱氢酶升高独立预测全因死亡率。
SARS-CoV-2 感染患者入院时肾功能衰竭很常见,与更多并发症和住院死亡率相关。我们的数据来自一个多中心登记处,因此无法对确切的死亡率风险进行评估。需要更多的研究来证实这些发现。